skip to Main Content

Sintilimab Plus Standard Chemotherapy Misses OS End Point in Metastatic Pancreatic Cancer

Newsfeed image, light gray text on dark gray background
Sintilimab (Tyvyt) plus standard-of-care chemotherapy failed to demonstrate a significant improvement in overall survival (OS) and progression-free survival (PFS) vs standard-of-care chemotherapy alone but did result in an improved objective response rate (ORR) in patients with metastatic or recurrent pancreatic adenocarcinoma (PDAC), according to findings from the phase 3 CISPD3 trial that were presented during the 2022 Gastrointestinal Cancers Symposium.


The standard of care for PDAC is the chemotherapy combination FOLFIRINOX (folinic acid, fluorouracil, irinotecan hydrochloride, and oxaliplatin) or modified-FOLFIRINOX (mFFX [folinic acid, irinotecan, oxaliplatin followed by fluorouracil]). Researchers in this study investigated whether sintilimab, a human immunoglobin G4 monoclonal antibody that binds to PD-1 and has shown efficacy in other cancer types, could improve outcomes for patients with PDAC in the first or second line. Read more . . . 

Back To Top